Mar 02, 2021 / 07:10PM GMT
Laura Christianson - Cowen and Company, LLC, Research Division - Research Associate
Hello. Welcome to our fireside chat with Medicenna Therapeutics. I have with me President and CEO, Fahar Merchant. Medicenna is developing Superkines as immunotherapy for cancer. Their lead program is in GBM, and then IL-2 program is another key focus.
We'll start with an overview of the company followed by Q&A. So feel free to put any questions you have on the online portal, and we'll get to them at the end of the presentation. And with that, I will hand it over to Fahar.
Fahar Merchant - Medicenna Therapeutics Corp. - Founder, Chairman, CEO & President
Well, thank you very much. I'm glad that you could make it to this presentation and fireside chat. Just to let you know, I'll be making forward-looking statements, so I encourage you to look at our regulatory filings for these risk factors, et cetera.
So the company is a Canadian company. We are based out of Toronto but listed both on NASDAQ as well as TSX. The company's focus, really, as was mentioned,
Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers